Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream Aug 19, 2025 07:00AM
Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors Sep 9, 2020 07:05AM
Lilly (LLY) Announces Agreement to Acquire Dermira (DERM) for $18.75/Share in $1.1 Billion Deal Jan 10, 2020 06:30AM
Lilly Announces Agreement to Acquire Dermira Jan 10, 2020 06:30AM
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 10, 2019 04:05PM
View Older Stories

Dec 10, 2019 08:31AM Dermira (DERM) Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
Dec 10, 2019 08:30AM Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
Nov 27, 2019 04:05PM Dermira to Participate in December Investor Conferences
Nov 14, 2019 04:05PM Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference
Nov 13, 2019 04:05PM Dermira Elects Halley E. Gilbert to its Board of Directors
Nov 11, 2019 04:10PM Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day
Nov 8, 2019 04:05PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2019 04:05PM Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 29, 2019 04:05PM Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019
Oct 17, 2019 04:10PM Dermira (DERM) Highlights Data from Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis
Oct 17, 2019 04:05PM Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
Oct 10, 2019 08:30AM Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
Oct 9, 2019 08:33AM Dermira (DERM) Commences Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Oct 9, 2019 08:30AM Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Oct 8, 2019 04:05PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 26, 2019 04:05PM Dermira to Participate in the 2019 Cantor Global Healthcare Conference
Aug 29, 2019 04:05PM Dermira to Participate in Upcoming Investor Conferences
Aug 7, 2019 04:05PM Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31, 2019 04:05PM Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019
Jun 25, 2019 08:40AM Dermira (DERM) Announces Almirall Exercises its Option on Lebrikizumab in Europe
Jun 25, 2019 01:30AM Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
Jun 11, 2019 04:00PM Dermira to Present at the Raymond James Life Sciences and MedTech Conference
May 7, 2019 04:05PM Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
Apr 30, 2019 04:05PM Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019
Apr 3, 2019 04:05PM Dermira to Present at the 18th Annual Needham Healthcare Conference
Mar 25, 2019 12:00AM Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
Mar 25, 2019 12:00AM Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
Mar 18, 2019 07:03AM Dermira (DERM) Reports Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
Mar 18, 2019 07:00AM Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
Mar 5, 2019 04:00PM Dermira to Present at the Cowen and Company 39th Annual Health Care Conference
Mar 1, 2019 08:15AM Dermira (DERM) Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis
Mar 1, 2019 08:00AM Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
Feb 26, 2019 04:01PM Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Feb 26, 2019 08:00AM Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting
Feb 22, 2019 08:04AM Dermira (DERM) Commences Proof-of-Concept Study to Evaluate QBREXZA (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
Feb 22, 2019 08:00AM Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
Feb 21, 2019 04:01PM Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Feb 19, 2019 04:01PM Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
Feb 12, 2019 02:00AM Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
Dec 11, 2018 05:07PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 4, 2018 07:30AM Dermira Enters into Credit Facility with Athyrium Capital Management
Nov 19, 2018 08:00AM Dermira to Present at Evercore ISI HealthCONx Conference
Nov 8, 2018 04:05PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 7, 2018 04:01PM Dermira Reports Third Quarter 2018 Financial Results
Oct 31, 2018 04:01PM Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
Oct 23, 2018 04:31PM Dermira (DERM) Reports Complete Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Oct 23, 2018 04:01PM Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Oct 9, 2018 04:01PM Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2018 08:30AM Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
Oct 2, 2018 08:30AM Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
View Older Stories